

Henry P Parkman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9529118/publications.pdf>

Version: 2024-02-01

270
papers

17,682
citations

10986

71
h-index

15732

125
g-index

287
all docs

287
docs citations

287
times ranked

6531
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of liquid and solid test meals on symptoms and gastric myoelectrical activity in patients with gastroparesis and functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2023, 35, e14376.	3.0	6
2	Constipation in Patients With Symptoms of Gastroparesis: Analysis of Symptoms and Gastrointestinal Transit. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 546-558.e5.	4.4	23
3	Baseline Predictors of Longitudinal Changes in Symptom Severity and Quality of Life in Patients With Suspected Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e407-e428.	4.4	5
4	Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e452-e464.	4.4	13
5	Meal Eating Characteristics of Patients with Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3872-3880.	2.3	6
6	Prevalence and clinical correlates of antinuclear antibody in patients with gastroparesis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14270.	3.0	3
7	Epidemiology of Gastroparesis in the United States. <i>Gastroenterology</i> , 2022, 162, 2136-2137.	1.3	4
8	Abdominal pain in gastroparesis. , 2022, , 173-188.		1
9	Hiatal hernias associated with acid reflux: size larger than 2 cm matters. <i>Ecological Management and Restoration</i> , 2022, , .	0.4	1
10	Healthcare resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3 years following the diagnosis of gastroparesis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14366.	3.0	8
11	Characterizing reflux on high resolution esophageal manometry with impedance. <i>BMC Gastroenterology</i> , 2022, 22, 112.	2.0	3
12	Normal Gastrointestinal Tract Physiology. , 2022, , 3-28.		2
13	Postprandial symptoms in patients with symptoms of gastroparesis: roles of gastric emptying and accommodation. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, G44-G59.	3.4	5
14	Progress in Gastroparesis - A Narrative Review of the Work of the Gastroparesis Clinical Research Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2684-2695.e3.	4.4	15
15	A cross-sectional study describing peripheral neuropathy in patients with symptoms of gastroparesis: associations with etiology, gastrointestinal symptoms, and gastric emptying. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	2
16	EndoFLIP and Pyloric Dilation for Gastroparesis Symptoms Refractory to Pyloromyotomy/Pyloroplasty. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2682-2690.	2.3	20
17	Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2021, 160, 76-87.e4.	1.3	49
18	Addition of small bowel transit scintigraphy to gastric emptying for assessment of patients with upper gastrointestinal symptoms. <i>Neurogastroenterology and Motility</i> , 2021, 33, e13987.	3.0	4

#	ARTICLE	IF	CITATIONS
19	Evaluating response in gastroparesis: Patient reported outcome measures and survey instruments. , 2021, , 451-460.		0
20	Prokinetic agents for gastroparesis. , 2021, , 323-339.		1
21	Studies from the NIH Gastroparesis Clinical Research Consortium: Towards improving our understanding and treatment of gastroparesis. , 2021, , 443-449.		0
22	Abdominal pain in gastroparesis: Prevalence, potential causes and management. , 2021, , 361-375.		0
23	Gastric emptying scintigraphy. , 2021, , 125-142.		0
24	Rheumatologic disorders in patients undergoing esophageal manometry: prevalence, symptom characteristics, and manometric findings. Ecological Management and Restoration, 2021, 34, .	0.4	2
25	Detection and characteristics of rumination syndrome in patients presenting for gastric symptom evaluation. Neurogastroenterology and Motility, 2021, 33, e14103.	3.0	1
26	COVID-19 infection manifesting as a severe gastroparesis flare. Medicine (United States), 2021, 100, e25467.	1.0	8
27	Functional Dyspepsia and Gastroparesis in Tertiary Care are Interchangeable Syndromes With Common Clinical and Pathologic Features. Gastroenterology, 2021, 160, 2006-2017.	1.3	141
28	Impact of patient position on esophageal motility disorders using high-resolution esophageal manometry with impedance (HREMI): supine versus upright swallows. Esophagus, 2021, 18, 880-888.	1.9	1
29	Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain. Clinical and Translational Gastroenterology, 2021, 12, e00362.	2.5	3
30	Editorial: on the road towards treatment of gastroparesis“ accelerating, but do we get closer? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 185-186.	3.7	0
31	Factors that contribute to the impairment of quality of life in gastroparesis. Neurogastroenterology and Motility, 2021, 33, e14087.	3.0	16
32	Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1090-1097.	3.7	23
33	Gastric half emptying time (T _{1/2}) for 4h gastric emptying scintigraphy simplifies reporting but reduces detection of gastroparesis. Neurogastroenterology and Motility, 2021, , e14261.	3.0	9
34	Body weight in patients with idiopathic gastroparesis. Neurogastroenterology and Motility, 2021, 33, e13974.	3.0	12
35	Surgical Treatment for Refractory Gastroparesis: Stimulator, Pyloric Surgery, or Both?. Journal of Gastrointestinal Surgery, 2020, 24, 2204-2211.	1.7	19
36	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 999-1000.	4.4	0

#	ARTICLE	IF	CITATIONS
37	Botulinum Toxin A Improves Symptoms of Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1396-1404.	2.3	18
38	Gastric Motility. , 2020, , 598-612.		2
39	Using gastric emptying scintigraphy to evaluate antral contractions and duodenal bolus propagation. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G203-G209.	3.4	8
40	Satiety testing in diabetic gastroparesis: Effects of insulin pump therapy with continuous glucose monitoring on upper gastrointestinal symptoms and gastric myoelectrical activity. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13720.	3.0	12
41	Factors Associated With Hospital Admissions and Readmissions in Patients With Gastroparesis Using the Nationwide Readmission Database. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 801-805.	2.2	7
42	Reflux Symptoms in Gastroparesis. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 428-438.	2.2	26
43	Gastroparesis. , 2020, , 265-280.		0
44	Vascular pressure bands on high-resolution esophageal manometry with impedance studies. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.4	2
45	Marijuana Use in Patients with Symptoms of Gastroparesis: Prevalence, Patient Characteristics, and Perceived Benefit. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2311-2320.	2.3	18
46	Symptom variability throughout the day in patients with gastroparesis. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13740.	3.0	7
47	Avoidant/restrictive food intake disorder symptoms are frequent in patients presenting for symptoms of gastroparesis. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13931.	3.0	49
48	Characterizing the proximal esophageal segment in patients with symptoms of esophageal dysmotility. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13888.	3.0	3
49	Which endosurgical treatment for gastroparesis: pyloromyotomy or gastric electrical stimulation?. <i>Endoscopy</i> , 2020, 52, 330-331.	1.8	6
50	Gastroparesis in the 2020s: New Treatments, New Paradigms. <i>Current Gastroenterology Reports</i> , 2020, 22, 23.	2.5	18
51	Endoscopic and Surgical Treatments for Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 539-556.	2.2	11
52	Modern Approaches for Evaluation and Treatment of Gastrointestinal Motility Disorders. <i>Gastroenterology Clinics of North America</i> , 2020, 49, xv-xvi.	2.2	1
53	Autonomic function in gastroparesis and chronic unexplained nausea and vomiting: Relationship with etiology, gastric emptying, and symptom severity. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13810.	3.0	37
54	Distal Esophageal Impedance Measured by High-resolution Esophageal Manometry With Impedance Suggests the Presence of Barrett's Esophagus. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 344-351.	2.4	2

#	ARTICLE	IF	CITATIONS
55	Gastroparesis. , 2020, , 720-730.		1
56	Absorbable antibacterial envelope in the surgical management of Twiddlerâ€™s syndrome in a patient with gastric electric stimulator: a case report. Digestive Medicine Research, 2020, 3, 76-76.	0.2	3
57	S0351â€™Characterizing Reflux on High Resolution Esophageal Manometry With Impedance. American Journal of Gastroenterology, 2020, 115, S173-S173.	0.4	1
58	Characterizing Abdominal Pain in Patients With Gastroparesis Into Neuropathic and Nociceptive Components. Journal of Clinical Gastroenterology, 2019, 53, 427-433.	2.2	15
59	Metoclopramide for the treatment of diabetic gastroparesis. Expert Review of Gastroenterology and Hepatology, 2019, 13, 711-721.	3.0	39
60	Caregiver Burden in Gastroparesis and GERD: Correlation with Disease Severity, Healthcare Utilization and Work Productivity. Digestive Diseases and Sciences, 2019, 64, 3451-3462.	2.3	10
61	Clinical and translational advances in esophageal squamous cell carcinoma. Advances in Cancer Research, 2019, 144, 95-135.	5.0	140
62	Effectiveness of gastric electrical stimulation in gastroparesis: Results from a large prospectively collected database of national gastroparesis registries. Neurogastroenterology and Motility, 2019, 31, e13714.	3.0	36
63	Role and safety of fundoplication in esophageal disease and dysmotility syndromes. Journal of Thoracic Disease, 2019, 11, S1610-S1617.	1.4	24
64	Abdominal Pain in Patients with Gastroparesis: Associations with Gastroparesis Symptoms, Etiology of Gastroparesis, Gastric Emptying, Somatization, and Quality of Life. Digestive Diseases and Sciences, 2019, 64, 2242-2255.	2.3	42
65	Validation of Diagnostic and Performance Characteristics of the Wireless Motility Capsule in Patients With Suspected Gastroparesis. Clinical Gastroenterology and Hepatology, 2019, 17, 1770-1779.e2.	4.4	53
66	Opioid Use and Potency Are Associated With Clinical Features, Quality of Life, and Use of Resources in Patients With Gastroparesis. Clinical Gastroenterology and Hepatology, 2019, 17, 1285-1294.e1.	4.4	60
67	Multiple Rapid Swallows (MRS) Complements Single-Swallow (SS) Analysis for High-Resolution Esophageal Manometry (HREM). Digestive Diseases and Sciences, 2019, 64, 2206-2213.	2.3	8
68	The American neurogastroenterology and motility society gastroparesis cardinal symptom indexâ€™daily diary (ANMS GCSIâ€™DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis. Neurogastroenterology and Motility, 2019, 31, e13553.	3.0	14
69	Role of Gastric Emptying in Symptoms of Gastroparesis. Gastrointestinal Disorders, 2019, 1, 391-402.	0.8	14
70	Influence of Gastric Emptying and Gut Transit Testing on Clinical Management Decisions in Suspected Gastroparesis. Clinical and Translational Gastroenterology, 2019, 10, e00084.	2.5	13
71	Effect of Chronic Domperidone Use on QT Interval. Journal of Clinical Gastroenterology, 2019, 53, 648-652.	2.2	22
72	Delayed Gastric Emptying Associates With Diabetic Complications in Diabetic Patients With Symptoms of Gastroparesis. American Journal of Gastroenterology, 2019, 114, 1778-1794.	0.4	34

#	ARTICLE	IF	CITATIONS
73	Cannabinoid Use in Patients With Gastroparesis and Related Disorders: Prevalence and Benefit. <i>American Journal of Gastroenterology</i> , 2019, 114, 945-953.	0.4	22
74	Towards a Fuller Assessment of Gastric Motility in Patients With Upper GI Dyspepsia: Time to Accommodate!. <i>American Journal of Gastroenterology</i> , 2019, 114, 16-18.	0.4	7
75	Ethnic, Racial, and Sex Differences in Etiology, Symptoms, Treatment, and Symptom Outcomes of Patients With Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1489-1499.e8.	4.4	43
76	Enhanced Gastric Emptying Scintigraphy to Assess Fundic Accommodation Using Intra-gastric Meal Distribution and Antral Contractility. <i>Journal of Nuclear Medicine Technology</i> , 2019, 47, 138-143.	0.8	19
77	Idiopathic Gastroparesis. , 2019, , 75-98.		0
78	Gastric Electric Stimulation for Refractory Gastroparesis. <i>Journal of Clinical Outcomes Management</i> , 2019, 26, 27-38.	1.7	10
79	Gastric Per Oral Endoscopic Myotomy (G-POEM) for the Treatment of Refractory Gastroparesis: Early Experience. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2405-2412.	2.3	108
80	Advances in the diagnosis and classification of gastric and intestinal motility disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 291-308.	17.8	168
81	Effect of Bifidobacterium infantis 35624 (Align) on the Lactulose Breath Test for Small Intestinal Bacterial Overgrowth. <i>Digestive Diseases and Sciences</i> , 2018, 63, 989-995.	2.3	9
82	Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD). <i>American Journal of Gastroenterology</i> , 2018, 113, 39-48.	0.4	20
83	Chronic nausea and vomiting: evaluation and treatment. <i>American Journal of Gastroenterology</i> , 2018, 113, 647-659.	0.4	64
84	Intra-gastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis. <i>Journal of Nuclear Medicine</i> , 2018, 59, 691-697.	5.0	48
85	Gastroparesis, Postprandial Distress. , 2018, , 269-281.		0
86	Gastric Emptying Studies. , 2018, , 309-315.		1
87	Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13196.	3.0	65
88	Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. <i>Gastroenterology</i> , 2018, 154, 65-76.e11.	1.3	117
89	Therapeutic response to domperidone in gastroparesis: A prospective study using the GCSI daily diary. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13246.	3.0	22
90	The content validity of the ANMS GCSI-DD in patients with idiopathic or diabetic gastroparesis. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 61.	1.9	12

#	ARTICLE	IF	CITATIONS
91	Post-Fundoplication Dumping Syndrome: A Frequent "Rare" Complication. <i>ACG Case Reports Journal</i> , 2018, 5, e1.	0.4	9
92	Utility of Esophageal High-Resolution Manometry in Clinical Practice: First, Do HRM. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3178-3186.	2.3	16
93	Gastroparesis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 41.	30.5	235
94	Rome IV Diagnostic Questionnaire Complements Patient Assessment of Gastrointestinal Symptoms for Patients with Gastroparesis Symptoms. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2231-2243.	2.3	20
95	Outcomes of surgical intervention for refractory gastroparesis: a systematic review. <i>Journal of Surgical Research</i> , 2018, 231, 263-269.	1.6	25
96	Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study. <i>PLoS ONE</i> , 2018, 13, e0194759.	2.5	33
97	Islet Cell Associated Autoantibodies and C-Peptide Levels in Patients with Diabetes and Symptoms of Gastroparesis. <i>Frontiers in Endocrinology</i> , 2018, 9, 32.	3.5	7
98	143 - Gastric Emptying Changes over Time in Gastroparesis: Comparison of Initial and 48 Week Follow up Gastric Emptying Tests in the Gastroparesis Registry of the Gastroparesis Consortium. <i>Gastroenterology</i> , 2018, 154, S-39.	1.3	5
99	Características del esfínter pilórico utilizando EndoFLIP® en gastroparesia. <i>Revista De Gastroenterología De México</i> , 2018, 83, 375-384.	0.2	17
100	Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13018.	3.0	77
101	The Burdens, Concerns, and Quality of Life of Patients with Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 879-893.	2.3	85
102	Gastric neuromuscular histology in patients with refractory gastroparesis: Relationships to etiology, gastric emptying, and response to gastric electric stimulation. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13068.	3.0	26
103	Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12981.	3.0	57
104	Methodologic considerations for studies of chronic nausea and vomiting in adults and children. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2017, 202, 28-39.	2.8	15
105	Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. <i>PLoS ONE</i> , 2017, 12, e0187772.	2.5	17
106	Taste and Smell Disturbances in Patients with Gastroparesis and Gastroesophageal Reflux Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 370-377.	2.4	17
107	Mirtazapine for symptom control in refractory gastroparesis. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1035-1041.	4.3	67
108	Chronic opioids in gastroparesis: Relationship with gastrointestinal symptoms, healthcare utilization and employment. <i>World Journal of Gastroenterology</i> , 2017, 23, 7310-7320.	3.3	40

#	ARTICLE	IF	CITATIONS
109	Future Directions in Understanding Nausea and Vomiting. , 2017, , 211-217.		0
110	Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study. Journal of Neurogastroenterology and Motility, 2016, 22, 650-655.	2.4	42
111	Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 <i>vs</i> type 2 diabetes. Neurogastroenterology and Motility, 2016, 28, 1001-1015.	3.0	51
112	Upper GI Disorders: Pathophysiology and Current Therapeutic Approaches. Handbook of Experimental Pharmacology, 2016, 239, 17-37.	1.8	4
113	Mo1599 Relation of Gastroparesis Symptom Severity to Gastric, Small Bowel, and Colon Transit and Contraction Profiles on Wireless Motility Capsule Testing in a Large Multicenter Cohort. Gastroenterology, 2016, 150, S725.	1.3	3
114	The impact of gastroparesis on diabetes control: Patient perceptions. Journal of Diabetes and Its Complications, 2016, 30, 826-829.	2.3	16
115	Fundamentals of Neurogastroenterology: Physiology/Motility â€“ Sensation. Gastroenterology, 2016, 150, 1292-1304.e2.	1.3	103
116	Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. Gastroenterology, 2016, 150, 1481-1491.	1.3	400
117	Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. Neurogastroenterology and Motility, 2016, 28, 1902-1914.	3.0	61
118	Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort. Digestive Diseases and Sciences, 2016, 61, 3545-3551.	2.3	52
119	Diagnosis and management of esophageal achalasia. BMJ, The, 2016, 354, i2785.	6.0	42
120	Mo1581 Impaired Quality of Life in Gastroparesis: Relationships to Symptoms of Gastroparesis. Gastroenterology, 2016, 150, S718.	1.3	2
121	Emerging strategies for the treatment of gastroparesis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 817-825.	3.0	16
122	Gastric Electric Stimulation for Refractory Gastroparesis: A Prospective Analysis of 151 Patients at a Single Center. Digestive Diseases and Sciences, 2016, 61, 168-175.	2.3	66
123	Minimally Invasive Fundoplication is Safe and Effective in Patients with Severe Esophageal Hypomotility. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2016, 11, 396-399.	0.9	0
124	Drugâ€drug interactions in pharmacologic management of gastroparesis. Neurogastroenterology and Motility, 2015, 27, 1528-1541.	3.0	21
125	Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized Study. Clinical Gastroenterology and Hepatology, 2015, 13, 1256-1263.e1.	4.4	75
126	Gastroparesis. Gastroenterology Clinics of North America, 2015, 44, 1-7.	2.2	78

#	ARTICLE	IF	CITATIONS
127	Improving Our Understanding of Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 2015, 44, xv-xvi.	2.2	2
128	Current advances in treatment of gastroparesis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1997-2008.	1.8	8
129	Diabetes-Related Autoantibodies in Diabetic Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1733-1737.	2.3	9
130	Advanced Training in Neurogastroenterology and Gastrointestinal Motility. <i>Gastroenterology</i> , 2015, 148, 881-885.	1.3	38
131	295 Pilot Study of the Safety, Feasibility, and Efficacy of Continuous Glucose Monitoring (CGM) and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG): A Multicenter, Longitudinal Trial by the NIDDK Gastroparesis Clinical Research Consortium (GPCRC). <i>Gastroenterology</i> , 2015, 148, S-64.	1.3	4
132	Su1428 Wireless Motility Capsule Gastric and Extragastric Transit and Pressure Characteristics in a Large Patient Cohort With Gastroparesis Symptoms: Relation to Scintigraphic Findings and Disease Etiology. <i>Gastroenterology</i> , 2015, 148, S-507-S-508.	1.3	4
133	Foods Provoking and Alleviating Symptoms in Gastroparesis: Patient Experiences. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1052-1058.	2.3	53
134	Outcomes and Factors Associated With Reduced Symptoms in Patients With Gastroparesis. <i>Gastroenterology</i> , 2015, 149, 1762-1774.e4.	1.3	110
135	Effect of dietary fat and food consistency on gastroparesis symptoms in patients with gastroparesis. <i>Neurogastroenterology and Motility</i> , 2015, 27, 501-508.	3.0	65
136	Assessing pyloric sphincter pathophysiology using EndoFLIP in patients with gastroparesis. <i>Neurogastroenterology and Motility</i> , 2015, 27, 524-531.	3.0	120
137	Idiopathic Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 59-68.	2.2	49
138	Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. <i>Neurogastroenterology and Motility</i> , 2014, 26, 521-528.	3.0	48
139	Bolus retention in hiatal hernia identified by high-resolution esophageal manometry with impedance. <i>Neurogastroenterology and Motility</i> , 2014, 26, 679-684.	3.0	3
140	Bodyweight in Patients with Idiopathic Gastroparesis: Roles of Symptoms, Caloric Intake, Physical Activity, and Body Metabolism. <i>Neurogastroenterology and Motility</i> , 2014, 26, 283-289.	3.0	11
141	Small Intestinal Bacterial Overgrowth in Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2014, 59, 645-652.	2.3	50
142	Association of low numbers of CD4 ⁺ positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1275-1284.	3.0	83
143	Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism <i>in vitro</i> . <i>Xenobiotica</i> , 2014, 44, 792-803.	1.1	5
144	Granisetron Transdermal System Improves Refractory Nausea and Vomiting in Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1231-1234.	2.3	41

#	ARTICLE	IF	CITATIONS
145	Gastroparesis. <i>Frontiers of Gastrointestinal Research</i> , 2014, , 25-37.	0.1	0
146	Surgical Outcomes After Gastric Electric Stimulator Placement for Refractory Gastroparesis. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 620-626.	1.7	22
147	Clinical Guideline: Management of Gastroparesis. <i>American Journal of Gastroenterology</i> , 2013, 108, 18-37.	0.4	904
148	Slow esophageal propagation velocity: association with dysphagia for solids. <i>Neurogastroenterology and Motility</i> , 2013, 25, e44-51.	3.0	3
149	Cholecystectomy and Clinical Presentations of Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1062-1073.	2.3	23
150	Use of a High Caloric Liquid Meal as an Alternative to a Solid Meal for Gastric Emptying Scintigraphy. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2001-2006.	2.3	40
151	Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC-ESI-MS/MS. <i>Xenobiotica</i> , 2013, 43, 1073-1083.	1.1	5
152	Effect of Nortriptyline on Symptoms of Idiopathic Gastroparesis. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2640.	7.4	149
153	The Influence of Race on Symptom Severity and Quality of Life in Gastroparesis. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 757-761.	2.2	31
154	The SNMMI and EANM Practice Guideline for Small-Bowel and Colon Transit 1.0. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2004-2013.	5.0	50
155	Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. <i>Neurogastroenterology and Motility</i> , 2013, 25, 427.	3.0	103
156	Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2013, 25, 815.	3.0	95
157	Migraine and Gastroparesis From a Gastroenterologist's Perspective. <i>Headache</i> , 2013, 53, 4-10.	3.9	32
158	Clinical Response and Side Effects of Metoclopramide. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 494-503.	2.2	61
159	Gastric Emptying Scintigraphy. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 209-215.	2.2	71
160	Scintigraphy for Evaluation of Patients for GI Motility Disorders—The Referring Physician's Perspective. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 76-78.	4.6	23
161	Fatigue: A Prevalent Symptom in Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2088-2095.	2.3	11
162	Exploring genetic variability in drug therapy by selecting a minimum subset of the most informative single nucleotide polymorphisms through approximation of a markov blanket in a kernel-induced space. , 2012, , .		3

#	ARTICLE	IF	CITATIONS
163	Ultrastructural differences between diabetic and idiopathic gastroparesis. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1573-1581.	3.6	104
164	DNA microarray SNP associations with clinical efficacy and side effects of domperidone treatment for gastroparesis. <i>Journal of Biomedical Informatics</i> , 2012, 45, 316-322.	4.3	4
165	Nausea and vomiting in diabetic and idiopathic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2012, 24, 217.	3.0	59
166	Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Indexâ€œDaily Diary (GCSIâ€œDD). <i>Neurogastroenterology and Motility</i> , 2012, 24, 456-463.	3.0	101
167	Clinicalâ€œhistological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. <i>Neurogastroenterology and Motility</i> , 2012, 24, 531.	3.0	164
168	Pain Management for Gastroparesis. , 2012, , 289-302.		0
169	Similarities and Differences Between Diabetic and Idiopathic Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 1056-1064.	4.4	174
170	Characteristics of Patients With Chronic Unexplained Nausea and Vomiting and Normal Gastric Emptying. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 567-576.e4.	4.4	212
171	Clinical Features of Idiopathic Gastroparesis Vary With Sex, Body Mass, Symptom Onset, Delay in Gastric Emptying, and Gastroparesis Severity. <i>Gastroenterology</i> , 2011, 140, 101-115.e10.	1.3	281
172	Cellular Changes in Diabetic and Idiopathic Gastroparesis. <i>Gastroenterology</i> , 2011, 140, 1575-1585.e8.	1.3	368
173	Dietary Intake and Nutritional Deficiencies in Patients With Diabetic or Idiopathic Gastroparesis. <i>Gastroenterology</i> , 2011, 141, 486-498.e7.	1.3	148
174	Characteristics of Nausea and Its Effects on Quality of Life in Diabetic and Idiopathic Gastroparesis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 317-321.	2.2	37
175	Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. <i>Neurogastroenterology and Motility</i> , 2011, 23, 8-23.	3.0	305
176	Variation of symptoms during the menstrual cycle in female patients with gastroparesis. <i>Neurogastroenterology and Motility</i> , 2011, 23, 625-e254.	3.0	25
177	Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects. <i>Digestive Diseases and Sciences</i> , 2011, 56, 115-124.	2.3	54
178	Gastric Emptying of Solids and Liquids for Evaluation for Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1138-1146.	2.3	84
179	Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2639-45.	2.3	94
180	Continuous Glucose Monitoring in Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2646-2655.	2.3	21

#	ARTICLE	IF	CITATIONS
181	Altered Expression of Ano1 Variants in Human Diabetic Gastroparesis. <i>Journal of Biological Chemistry</i> , 2011, 286, 13393-13403.	3.4	95
182	Bloating in Gastroparesis: Severity, Impact, and Associated Factors. <i>American Journal of Gastroenterology</i> , 2011, 106, 1492-1502.	0.4	52
183	The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 313-322.	3.7	123
184	Effect of Atilmotin, a Motilin Receptor Agonist, on Esophageal, Lower Esophageal Sphincter, and Gastric Pressures. <i>Digestive Diseases and Sciences</i> , 2010, 55, 300-306.	2.3	13
185	Gastric Neuromuscular Pathology in Gastroparesis: Analysis of Full-Thickness Antral Biopsies. <i>Digestive Diseases and Sciences</i> , 2010, 55, 359-370.	2.3	96
186	Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. <i>Neurogastroenterology and Motility</i> , 2010, 22, 113-133.	3.0	171
187	Assessment of symptoms during gastric emptying scintigraphy to correlate symptoms to delayed gastric emptying. <i>Neurogastroenterology and Motility</i> , 2010, 22, 539-45.	3.0	50
188	Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsule. <i>Neurogastroenterology and Motility</i> , 2010, 22, 527-33, e117.	3.0	91
189	Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. <i>Neurogastroenterology and Motility</i> , 2010, 22, 874.	3.0	185
190	Psychological Dysfunction Is Associated With Symptom Severity but Not Disease Etiology or Degree of Gastric Retention in Patients With Gastroparesis. <i>American Journal of Gastroenterology</i> , 2010, 105, 2357-2367.	0.4	103
191	Abdominal Pain Is a Frequent Symptom of Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 676-681.	4.4	100
192	Gastric Electrical Stimulation With Enterra Therapy Improves Symptoms From Diabetic Gastroparesis in a Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 947-954.e1.	4.4	186
193	Identification of Novel Metoclopramide Metabolites in Humans: In Vitro and In Vivo Studies. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1295-1307.	3.3	24
194	Treatment of patients with diabetic gastroparesis. <i>Gastroenterology and Hepatology</i> , 2010, 6, 1-16.	0.1	20
195	Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. <i>Xenobiotica</i> , 2009, 39, 749-756.	1.1	8
196	Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, G1107-G1114.	3.4	70
197	Wireless Capsule Motility: Comparison of the SmartPill® GI Monitoring System with Scintigraphy for Measuring Whole Gut Transit. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2167-2174.	2.3	202
198	Factors Contributing to Hospitalization for Gastroparesis Exacerbations. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2404-2409.	2.3	33

#	ARTICLE	IF	CITATIONS
199	Development and content validity of a gastroparesis cardinal symptom index daily diary. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 670-680.	3.7	110
200	376 Enterra® Gastric Electrical Stimulation for Diabetic Gastroparesis: Results from a Multicenter Randomized Study. <i>Gastroenterology</i> , 2009, 136, A-61-A-62.	1.3	8
201	Tests of Gastric Neuromuscular Function. <i>Gastroenterology</i> , 2009, 136, 1526-1543.	1.3	57
202	Assessment of Gastric Emptying and Small-Bowel Motility: Scintigraphy, Breath Tests, Manometry, and SmartPill. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2009, 19, 49-55.	1.4	38
203	Investigation of Colonic and Whole-Gut Transit With Wireless Motility Capsule and Radiopaque Markers in Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 537-544.	4.4	297
204	The Gastrointestinal Motility Laboratory. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2009, 19, 171-184.	1.4	8
205	Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 186-196.	3.7	293
206	Predictive Factors for Clinical Improvement with Enterra Gastric Electric Stimulation Treatment for Refractory Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2072-2078.	2.3	126
207	Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. <i>Neurogastroenterology and Motility</i> , 2008, 20, 311-319.	3.0	261
208	Cyclic vomiting syndrome in adults. <i>Neurogastroenterology and Motility</i> , 2008, 20, 269-284.	3.0	172
209	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. <i>American Journal of Gastroenterology</i> , 2008, 103, 753-763.	0.4	588
210	Transsphincteric pH Profile at the Gastroesophageal Junction. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 630-634.	4.4	13
211	Persistent Nausea and Abdominal Pain in a Patient With Delayed Gastric Emptying. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1309-1314.	4.4	4
212	T1345 The Pathological Basis of Gastroparesis. <i>Gastroenterology</i> , 2008, 134, A-536.	1.3	4
213	Symptoms of Gastroparesis: Use of the Gastroparesis Cardinal Symptom Index in Symptomatic Patients Referred for Gastric Emptying Scintigraphy. <i>Digestion</i> , 2008, 78, 144-151.	2.3	64
214	Botulinum Toxin A for the Treatment of Delayed Gastric Emptying. <i>American Journal of Gastroenterology</i> , 2008, 103, 416-423.	0.4	318
215	Gastroparesis-Related Hospitalizations in the United States: Trends, Characteristics, and Outcomes, 1995-2004. <i>American Journal of Gastroenterology</i> , 2008, 103, 313-322.	0.4	267
216	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. <i>Journal of Nuclear Medicine Technology</i> , 2008, 36, 44-54.	0.8	295

#	ARTICLE	IF	CITATIONS
217	Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, G1384-G1391.	3.4	36
218	The Gastrointestinal Motility Laboratory. <i>Gastroenterology Clinics of North America</i> , 2007, 36, 515-529.	2.2	2
219	High-resolution solid-state manometry of the antropyloroduodenal region. <i>Neurogastroenterology and Motility</i> , 2007, 19, 188-195.	3.0	72
220	Gastric electric stimulation for the treatment of gastroparesis. <i>Current Gastroenterology Reports</i> , 2007, 9, 286-294.	2.5	24
221	Advances in the management of gastroparesis. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 283-293.	0.8	14
222	Gastric Emptying Scintigraphy Results in the ROME III Subgroup Classifications for Functional Gastrointestinal Disorders. <i>American Journal of Gastroenterology</i> , 2007, 102, S507.	0.4	1
223	Regional gastric emptying abnormalities in functional dyspepsia and gastro-oesophageal reflux disease. <i>Neurogastroenterology and Motility</i> , 2006, 18, 894-904.	3.0	68
224	Treatment of gastroparesis: a multidisciplinary clinical review. <i>Neurogastroenterology and Motility</i> , 2006, 18, 263-283.	3.0	316
225	Abnormal Ghrelin and Pancreatic Polypeptide Responses in Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1339-1346.	2.3	54
226	Training in Gastrointestinal Motility. <i>Digestive Diseases</i> , 2006, 24, 221-227.	1.9	11
227	Differential effects of sham feeding and meal ingestion on ghrelin and pancreatic polypeptide levels: evidence for vagal efferent stimulation mediating ghrelin release ¹ . <i>Neurogastroenterology and Motility</i> , 2005, 17, 348-354.	3.0	74
228	Chronic intestinal pseudo-obstruction. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 3-11.	0.8	42
229	Regional Postprandial Differences in pH Within the Stomach and Gastroesophageal Junction. <i>Digestive Diseases and Sciences</i> , 2005, 50, 2276-2285.	2.3	120
230	Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 833-839.	1.0	190
231	Management of Delayed Gastric Emptying. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 642-646.	4.4	11
232	Regional gastric contractility alterations in a diabetic gastroparesis mouse model: effects of cholinergic and serotonergic stimulation. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 287, G612-G619.	3.4	41
233	Multichannel Electrogastrography (EGG) in Symptomatic Patients: A Single Center Study. <i>American Journal of Gastroenterology</i> , 2004, 99, 478-485.	0.4	31
234	REVIEW: The Use of Botulinum Toxin for the Treatment of Gastrointestinal Motility Disorders. <i>Digestive Diseases and Sciences</i> , 2004, 49, 165-175.	2.3	43

#	ARTICLE	IF	CITATIONS
235	Multichannel Electrogastrography (EGG) in Normal Subjects: A Multicenter Study. <i>Digestive Diseases and Sciences</i> , 2004, 49, 594-601.	2.3	50
236	Achalasia Presenting After Operative and Nonoperative Trauma. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1818-1821.	2.3	28
237	American Gastroenterological Association medical position statement: Diagnosis and treatment of gastroparesis. <i>Gastroenterology</i> , 2004, 127, 1589-1591.	1.3	191
238	American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. <i>Gastroenterology</i> , 2004, 127, 1592-1622.	1.3	644
239	Simultaneous assessment of gastric accommodation and emptying: studies with liquid and solid meals. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1155-60.	5.0	52
240	Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. <i>Digestive Diseases and Sciences</i> , 2003, 48, 488-497.	2.3	103
241	Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. <i>Neurogastroenterology and Motility</i> , 2003, 15, 89-102.	3.0	286
242	Neurotrophin-3 Improves Functional Constipation. <i>American Journal of Gastroenterology</i> , 2003, 98, 1338-1347.	0.4	74
243	Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 285, G291-G297.	3.4	56
244	New advances in the diagnosis and management of nausea and vomiting. <i>The Case Manager</i> , 2002, 13, 83-87.	0.2	1
245	Treatment of Idiopathic Gastroparesis With Injection of Botulinum Toxin Into The Pyloric Sphincter Muscle. <i>American Journal of Gastroenterology</i> , 2002, 97, 1653-1660.	0.4	194
246	Simultaneous measurement of gastric emptying with a simple muffin meal using [13C]octanoate breath test and scintigraphy in normal subjects and patients with dyspeptic symptoms. <i>Digestive Diseases and Sciences</i> , 2002, 47, 1657-1663.	2.3	80
247	AGA technical review on nausea and vomiting. <i>Gastroenterology</i> , 2001, 120, 263-286.	1.3	220
248	Effect of meal size and test duration on gastric emptying and gastric myoelectrical activity as determined with simultaneous [13C]octanoate breath test and electrogastrography in normal subjects using a muffin meal. <i>Digestive Diseases and Sciences</i> , 2001, 46, 2643-2650.	2.3	26
249	Myosin light chain phosphorylation correlates with contractile force in guinea pig gallbladder muscle. <i>Digestive Diseases and Sciences</i> , 2001, 46, 176-181.	2.3	7
250	Extending gastric emptying scintigraphy from two to four hours detects more patients with gastroparesis. <i>Digestive Diseases and Sciences</i> , 2001, 46, 24-29.	2.3	160
251	Use of simultaneous high-resolution endoluminal sonography (HRES) and manometry to characterize high pressure zone of distal esophagus. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1660-1666.	2.3	29
252	Whole Gut Transit Scintigraphy in The Clinical Evaluation of Patients With Upper and Lower Gastrointestinal Symptoms. <i>American Journal of Gastroenterology</i> , 2000, 95, 2838-2847.	0.4	152

#	ARTICLE	IF	CITATIONS
253	Subtypes of muscarinic receptors regulating gallbladder cholinergic contractions. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 276, G1243-G1250.	3.4	17
254	Cholinergic effects on human gastric motility. <i>Gut</i> , 1999, 45, 346-354.	12.1	96
255	Nonulcer dyspepsia. <i>Current Treatment Options in Gastroenterology</i> , 1998, 1, 15-19.	0.8	0
256	Measurement of gastrointestinal motility in the GI laboratory. <i>Gastroenterology</i> , 1998, 115, 747-762.	1.3	317
257	Effect of gastric acid suppressants on human gastric motility. <i>Gut</i> , 1998, 42, 243-250.	12.1	183
258	Dual effects of PACAP on guinea pig gallbladder muscle via PACAP-preferring and VIP/PACAP-preferring receptors. <i>American Journal of Physiology - Renal Physiology</i> , 1997, 272, G1433-G1438.	3.4	10
259	Comparison of scintigraphy and lactulose breath hydrogen test for assessment of orocecal transit: lactulose accelerates small bowel transit. <i>Digestive Diseases and Sciences</i> , 1997, 42, 10-18.	2.3	126
260	Electrogastrography and Gastric Emptying Scintigraphy Are Complementary for Assessment of Dyspepsia. <i>Journal of Clinical Gastroenterology</i> , 1997, 24, 214-219.	2.2	112
261	Delayed gastric emptying and decreased antral contractility in normal premenopausal women compared with men. <i>American Journal of Gastroenterology</i> , 1997, 92, 968-75.	0.4	91
262	Erythromycin inhibits rabbit pyloric smooth muscle through neuronal motilin receptors. <i>Gastroenterology</i> , 1996, 111, 682-690.	1.3	25
263	Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. <i>Digestive Diseases and Sciences</i> , 1996, 41, 2025-2031.	2.3	81
264	Optimal evaluation of patients with nonobstructive esophageal dysphagia. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1355-1368.	2.3	65
265	Influence of age, gender, and menstrual cycle on the normal electrogastrogram. <i>American Journal of Gastroenterology</i> , 1996, 91, 127-33.	0.4	79
266	Gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in rabbit stomach. <i>American Journal of Physiology - Renal Physiology</i> , 1995, 269, G418-G426.	3.4	33
267	Gastrointestinal motility and dysmotility: an update on techniques available for evaluation. <i>American Journal of Gastroenterology</i> , 1995, 90, 869-92.	0.4	79
268	Malignancy-induced secondary achalasia. <i>Dysphagia</i> , 1994, 9, 292-6.	1.8	10
269	Malignancy-induced secondary achalasia. <i>Dysphagia</i> , 1993, 8, 292-6.	1.8	3
270	Disorders of gastric emptying. , 0, , 903-935.		0